USMLE Step 3 Question #487

487) 57-year-old male with a history of mild COPD has been using albuterol as needed to manage his COPD without any other maintenance medications. Recently he has been experiencing a greater degree of shortness of breath, wheezing and a productive cough. Pulmonary function tests demonstrate a FEV1 that is 60% of predicted. What is the next best step for management of his COPD?

A. Add budesonide to treatment regimen

B. Add rofilumast to treatment regimen

C. Add tiotropium to treatment regimen

D. Add tiotropium plus fluticasone to treatment regimen

E. Add carbocystine to treatment regimen

 

USMLE STep 3 Question #486

A 56-year-old male with Type II diabetes presents to you today for a follow-up visit. Three months prior his A1c was 8.9% and he was started on metformin. Today his A1c is 7.4%. He is significantly overweight with a BMI of 33. You would like to initiate another medication for glucose control, specifically one that does not carry a risk of weight gain. Which of the following drugs is weight neutral?

  • A.  Glimepride
  • B. Rosiglitazone
  • C.  Pioglitazone
  • D. Sitagliptin
  • E. Glyburide

Question of the Week #485

485. A 10-year-old female presents with a 3 week history of cough.  Initially she had a runny nose and was tired with a slight cough but as the runny nose resolved the cough seemed to get worse.  She states that the cough is dry sounding and occurs during the day and night.  She describes having coughing spasms that occasionally end in vomiting but between episodes of coughing she is fine.  Her mom reports that during a coughing spasm she will gasp for air and sometimes make a “whooping” noise.  A nasopharyngeal swab confirms a diagnosis of Bordatella pertussis.  Which of the following is true?

A. Her 3-month-old brother should be treated with azithromycin as prophylaxis

B. She should be started on azithromycin for more rapid resolution of cough.

C. Her classmates should be treated with clarithromycin as prophylaxis

D. She will have lifelong natural immunity against Bordatella pertussis.

E. Her classmates should receive a Tdap booster regardless of their vaccination status

Question of the Week #484

A 50-year-old African american woman presents to your clinic with increased thirst and increased urination. You review her old records and it appears like she had a Chest X-ray in the ER last year that showed bilateral hilar lymphadenopathy. She was advised follow-up but she did not comply at that time. Upon examination, you discover some subcutaneous skin nodules and biopsy of one of these comes back positive for non-caseating granulomas.

Laboratory studies from a week ago show:

Hemoglobin 15.2gm%

Calcium : 11.6mg%

Creatinine : 1.0mg%

Which of the following investigations may explain the underlying mechanism of her Hypercalcemia?

A. Biopsy of Hilar Lymph Node

B. 25 Hydroxy Vitamin D Level

C. PTH related peptides

D. 1,25 di-hydroxy Vitamin D level

E. Serum Protein Electrophoresis

Question of the Week# 483

A 50-year-old previously healthy man comes to his physician for a scheduled follow-up examination. He works as an electrician, which involves a significant amount of physical activity when working. He says he also runs 5 miles twice a week and is on a low-fat, low-cholesterol diet. His father died of a ‘heart attack’ at the age of 54, and he has smoked one pack of cigarettes daily for the past 25 years. He denies alcohol or illicit drug use. He says he leads a low-stress lifestyle and has no complaints. His current medication include lisinopril. On presentation, his blood pressure is 135/85 mm Hg. Laboratory studies from a week ago show:

Total cholesterol     287 mg/dL

HDL                        65 mg/dL

LDL                        180 mg/dL

Which of the following is the best next step in patient care?

A Initiate drug therapy for control of his hyperlipidemia
B Educate the patient about diet and exercise and repeat the tests within 4 weeks
C Educate the patient about diet and exercise and repeat the tests within a year
D Initiate a mandatory low-fat diet for the patient
E No intervention is indicated

 

Question of the Week #482

A 63-year-old woman comes to the emergency department complaining of severe midabdominal pain. She reports that the pain has increased in intensity over the past few days. There has been no associated nausea or vomiting, no change in bowel habits, and no relief afforded by position changes. She is postmenopausal and does not take hormone replacement therapy. She has a 30-year history of hypertension, and has been noncompliant with her therapy of calcium channel blocker and thiazide diuretic. On examination her abdomen is obese but there is a suggestion of a nontender, pulsatile mass in the epigastric region. The remainder of the physical examination is normal. Which of the following is the best next step in management?

A. Abdominal ultrasound
B. Abdominal CT scan without contrast
C. Abdominal CT scan with contrast
D. Angiography
E. Observation

Question of the Week #483

BACKGROUND:

Beta-blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.

METHODS:

In a multicenter, double blind, and randomized parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily). Patients were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary endpoints were all-cause mortality and the composite endpoint of all-cause mortality or all-cause admission. Analysis was done by intention to treat.

FINDINGS:

The mean study duration was 58 months (SD 6). The mean ejection fraction was 0.26 (0.07) and the mean age 62 years (11). The all-cause mortality was 34% (512 of 1511) for carvedilol and 40% (600 of 1518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.93], p=0.0017). The reduction of all-cause mortality was consistent across predefined subgroups. Incidence of side effects and drug withdrawals did not differ by much between the two study groups.

 

  1. To which of the following patients are the results of this clinical trial applicable?
    1. A 62-year-old male with primarily diastolic congestive heart failure.
    2. A 75-year-old female with systolic dysfunction and an EF of 45%.
    3. A 56-year-old male with NYHA class I systolic heart failure.
    4. A newly diagnosed 66-year-old male who has yet to begin treatment for his NYHA class II systolic heart failure.
    5. A 68-year-old male with NYHA class II systolic heart failure and EF 30%.

 

%d bloggers like this: